Teva Pharmaceutical Industries ( NYSE:TEVA ) Full Year 2024 Results Key Financial Results Revenue: US$16.5b (up 4.4... This pharma stock has made strong gains over the past 12 months thanks to its ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Teva's long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company's long-acting formulation of schizophrenia drug risperidone. The ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

After hours: 8:00:00 p.m. EST ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...